Literature DB >> 31298352

MicroRNA-760 inhibits the biological progression of colorectal carcinoma by directly targeting FOXA1 and regulating epithelial-to-mesenchymal transition and PI3K/AKT signaling pathway.

K Cong1, C-G Li, Y-H Wei, K Zhang, H-B Xu.   

Abstract

OBJECTIVE: Colorectal carcinoma (CRC) is one of the most common factors for tumor-associated mortalities globally. In recent years, microRNAs (miRNAs) have been identified as novel therapeutic biomarkers for cancer treatment. The purpose of the current study was to unravel the clinical significance and underlying molecular mechanisms of miR-760 in CRC progression. PATIENTS AND METHODS: Fifty-four pairs of CRC tissue samples and adjacent para-carcinoma tissue samples were collected from CRC patients who underwent surgical resection. We measured miR-760 expressions in CRC using quantitative Real-time polymerase chain reaction (qRT-PCR) analysis. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assays and transwell assays were performed to determine the functions of miR-760 in CRC cell proliferation, invasion and migration. Dual-luciferase reporter assays and Western blots were used to investigate the underlying molecular mechanisms. Moreover, the association between miR-760 expressions and clinicopathological features was analyzed.
RESULTS: In this study, the results showed that the down-regulated miR-760 expressions were related to the poor prognosis and malignant clinicopathologic features of CRC patients. Furthermore, functional assays revealed that miR-760 restoration obviously suppressed CRC cell proliferation, migration and invasion through modulating phosphatidylinositol 3-kinase/ protein kinase B (PI3K/AKT) pathway and epithelial-mesenchymal transition (EMT). FOXA1 was also considered as a functional target of miR-760 in CRC cells. Furthermore, miR-760 up-regulation also significantly repressed tumorigenesis in vivo.
CONCLUSIONS: These results suggested that miR-760 exerted cancer-suppressive functions in CRC, providing a therapeutic strategy for CRC treatment.

Entities:  

Year:  2019        PMID: 31298352     DOI: 10.26355/eurrev_201907_18310

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Genome-Wide Analysis of the FOXA1 Transcriptional Network Identifies Novel Protein-Coding and Long Noncoding RNA Targets in Colorectal Cancer Cells.

Authors:  Sarah B Lazar; Lorinc Pongor; Xiao Ling Li; Ioannis Grammatikakis; Bruna R Muys; Emily A Dangelmaier; Christophe E Redon; Sang-Min Jang; Robert L Walker; Wei Tang; Stefan Ambs; Curtis C Harris; Paul S Meltzer; Mirit I Aladjem; Ashish Lal
Journal:  Mol Cell Biol       Date:  2020-10-13       Impact factor: 4.272

Review 2.  Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer.

Authors:  Zeinab Moafian; Abolfazl Maghrouni; Arash Soltani; Seyed Isaac Hashemy
Journal:  Mol Biol Rep       Date:  2021-05-31       Impact factor: 2.316

3.  Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.

Authors:  Xi Zhang; Li Ma; Li Zhai; Dong Chen; Yong Li; Zhongjun Shang; Zongmei Zhang; Yanzhang Gao; Wei Yang; Yixun Li; Yuqing Pan
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

4.  Microarray Identifies a Key Carcinogenic Circular RNA 0008594 That Is Related to Non-Small-Cell Lung Cancer Development and Lymph Node Metastasis and Promotes NSCLC Progression by Regulating the miR-760-Mediated PI3K/AKT and MEK/ERK Pathways.

Authors:  Qiushi Wang; Chunhua Yan; Pengfei Zhang; Guanghua Li; Ruidong Zhu; Hanbing Wang; Libo Wu; Guangquan Xu
Journal:  Front Oncol       Date:  2021-11-11       Impact factor: 6.244

5.  Circ_0007031 Serves as a Sponge of miR-760 to Regulate the Growth and Chemoradiotherapy Resistance of Colorectal Cancer via Regulating DCP1A.

Authors:  Yuanyuan Wang; Hua Wang; Jian Zhang; Zhifen Chu; Pu Liu; Xing Zhang; Chao Li; Xiaosong Gu
Journal:  Cancer Manag Res       Date:  2020-09-14       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.